{"chebi_id":"7494","chebi_name":"nefazodone","chebi_synonyms":["1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one","2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one","Nefazodone","nefazodona","n\u00e9fazodone","nefazodonum"],"diffprof_id_observed":["MTBLS2825_0001_00000004","MTBLS2878_0001_00000001","MTBLS3750_0002_00000006","MTBLS5943_0002_00000001"],"diffprof_id_var_observed":[],"inchikey":"VRBKIVRKKCLPHA-UHFFFAOYSA-N","inn_name":"nefazodone","iupac_name":"2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3<em>H</em>-1,2,4-triazol-3-one","num_study_observed":4,"reactome_ids":["R-HSA-112311","R-HSA-112315","R-HSA-112316","R-HSA-1430728","R-HSA-211859","R-HSA-211945","R-HSA-380615"],"reactome_names":["Neurotransmitter clearance","Transmission across Chemical Synapses","Neuronal System","Metabolism","Biological oxidations","Phase I - Functionalization of compounds","Serotonin clearance from the synaptic cleft"],"study_id_observed":["MTBLS2825","MTBLS2878","MTBLS3750","MTBLS5943"],"study_id_var_observed":[],"synonym_name":"Nefazodone"}